(PSYCHIATRIC TIMES) - The autopsy of a man evaluated for dementia with Pittsburgh compound B has revealed for the first time that the imaging agent binds to the protein in amyloid plaques that characterize Alzheimer's disease in the human brain. The findings come from a study by researchers at Massachusetts General Hospital that appeared in the March issue of Archives of Neurology.
The autopsy confirmed the diagnosis of dementia with Lewy bodies and produced several findings characteristic of Alzheimer's disease. But, while some plaques that typify Alzheimer's were seen, most amyloid-beta was found in the walls of blood vessels, a condition known as cerebral amyloid angiopathy.
"The distribution of amyloid seen at autopsy matched the overall distribution seen in the Pittsburgh compound B (PIB) imaging study; levels were higher in the cerebral cortex than in other areas of the brain," said coauthor Dr. Matthew Frosch of the MassGeneral Institute for Neurodegenerative Diseases. "Features of Alzheimer's pathology, amyloid plaques and neurofibrillary tangles, were observed, but not at a level that would support a separate diagnosis of Alzheimer's disease."
The researchers noted that, while their results confirm that uptake of PIB indicates the presence of amyloid in the brain, a positive PIB-PET scan cannot be equated with a definitive Alzheimer's diagnosis.
For full article, please visit: